Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
5.60
+0.21 (3.80%)
Aug 21, 2026, 4:08 PM HKT

Sino Biopharmaceutical Stock Forecast

Stock Price Forecast

According to 23 analysts polled by S&P Global, Sino Biopharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $8.39. The average 1-year stock price forecast is 49.96% higher than the current stock price, while the lowest is $5.64 (+0.80%) and the highest is $10.89 (+94.64%).

Price Target: $8.39 (+49.96%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$5.64$8.39$8.67$10.89
Change+0.80%+49.96%+54.96%+94.64%

Analyst Ratings

The average analyst rating for Sino Biopharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy181717171616
Buy334444
Hold111122
Sell000000
Strong Sell000000
Total222122222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
CICC
No rating
CICC
Buy
Maintains
$8.90
BuyMaintains$8.90+59.07%Aug 21, 2026
Unknown Analyst
Citi
No rating
Citi
Buy
Maintains
$10.00$10.80
BuyMaintains$10.00$10.80+93.03%Aug 21, 2026
Morgan Stanley
Morgan Stanley
Buy
Maintains
$7.80
BuyMaintains$7.80+39.41%Aug 19, 2026
Unknown Analyst
Daiwa
No rating
Daiwa
Buy
Maintains
$7.00
BuyMaintains$7.00+25.11%Aug 12, 2026
Unknown Analyst
UOB Kay Hian
No rating
UOB Kay Hian
Buy
Maintains
$7.20
BuyMaintains$7.20+28.69%Jul 25, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
36.29B
from 31.83B
Increased by 14.00%
Revenue Next Year
39.16B
from 36.29B
Increased by 7.90%
EPS This Year
0.24
from 0.25
Decreased by -6.30%
EPS Next Year
0.25
from 0.24
Increased by 7.01%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
26.86B26.03B26.20B28.87B31.83B36.29B
Revenue Growth
13.59%-3.11%0.67%10.18%10.28%14.00%
Gross Profit
21.53B21.54B21.21B23.53B26.13B29.99B
Gross Margin
80.15%82.76%80.95%81.51%82.07%82.65%
Operating Income
4.63B5.39B5.44B5.80B6.29B8.45B
Net Income
14.61B2.54B2.33B3.50B2.34B3.95B
EPS
----0.250.24
EPS Growth
----33.44%-6.30%
Forward PE
12.3320.6317.7817.4821.6220.30
Dividend / Share
0.070.110.040.070.090.08
Dividend Growth
5.60%62.87%-58.16%48.12%36.61%-8.86%
Free Cash Flow
-196.74M2.99B3.01B3.90B6.60B7.17B
No. Analysts
-----20
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High37.8B
Avg36.3B
Low35.3B

Revenue Growth

Revenue Growth202620272028
High
18.7%
Avg
14.0%
Low
10.9%

EPS Forecast

EPS202620272028
High0.28
Avg0.24
Low0.18

EPS Growth

EPS Growth202620272028
High
11.0%
Avg
-6.3%
Low
-28.6%